Clinical Outcome of Two-piece Zirconia Implants in Immediate Implant Placement
Launched by MEDICAL UNIVERSITY OF GRAZ · May 10, 2022
Trial Information
Current as of May 14, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new type of dental implant made from zirconia, which is a white ceramic material. The goal is to find out if these two-piece zirconia implants are as effective as traditional titanium implants for patients who need immediate dental implants—meaning the implant is placed right after a tooth is removed. They are currently looking for participants aged 18 and older who are in good health, have good oral hygiene, and have gaps where teeth are missing in their upper or lower jaws.
To take part in the trial, participants should not smoke and should not have certain health issues that could complicate the implant procedure, like active gum disease or uncontrolled diabetes. Those who join the study can expect to receive an implant and will be monitored to see how well it works compared to the standard titanium option. This research is important because it could help determine if zirconia implants are a viable choice for patients needing immediate tooth replacements.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Patients giving informed consent to participate in the clinical trial and fulfil the following criteria will be included in the investigation:
- • 1. good oral hygiene standard;
- • 2. good general health;
- • 3. 18 years or older;
- • 4. non-smokers;
- • 5. presence of single-tooth or multiple gaps in the mandible or the maxilla;
- • 6. intact facial bone wall;
- • 7. sufficient bone volume to support an implant of at least 10 mm length.
- • 8. Teeth with removable periapical lesions are included.
- Exclusion Criteria:
- Primary exclusion criteria are as follows:
- • 1. parafunctional habits;
- • 2. active periodontitis;
- • 3. smoking;
- • 4. pregnancy;
- • 5. acute or chronic medical conditions for which implant therapy has always been considered a contraindication: uncontrolled diabetes (HbA1c \>8.0%), mucosal disease, untreated periodontitis, immunological disorders, active malignancy, alcoholism, condition after radiation therapy to the head and neck area and antiresorptive therapy.
- Secondary exclusion criteria will be applied at surgical procedure:
- • 6. loss of facial bone wall due to extraction procedure;
- • 7. insufficient primary stability (less than 32Ncm insertion torque).
About Medical University Of Graz
The Medical University of Graz, a leading institution in Austria, is dedicated to advancing medical knowledge and improving patient care through innovative research and clinical trials. Renowned for its interdisciplinary approach, the university collaborates with various healthcare professionals and researchers to explore cutting-edge therapies and treatments. With a commitment to ethical standards and patient safety, the Medical University of Graz actively contributes to the global medical community by facilitating rigorous clinical trials that aim to translate scientific discoveries into practical applications for improved health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Graz, Styria, Austria
Patients applied
Trial Officials
Raoul Polansky, DMD
Principal Investigator
Department of Dentistry and Oral Health, Medical University of Graz
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials